Cardiovascular safety profile of currently available diabetic drugs. - Wikidata - wikimedia - TriplyDB

Cardiovascular safety profile of currently available diabetic drugs.

Cardiovascular safety profile of currently available diabetic drugs.

http://www.wikidata.org/entity/Q34971736

about

Diabetes Dyslipidemia Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure.Disease, Models, Variants and Altered Pathways-Journeying RGD Through the Magnifying Glass.Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.

P2860

Q26750905-EE4E9FFF-BD04-4DB4-B6C3-350341AB6687 Q33801801-E41A5D74-E2A7-4EDA-9014-FC82E1EB6F2D Q33815573-D65A4D3C-33C6-4F59-9CA6-01D1B9534EA4 Q36427543-27BF350F-4590-4C6A-99C7-9ACF488EB4C5 Q37620904-290F64D0-AEFC-4D49-856E-F591158648D9 Q40106543-620DE38F-EC9C-45CB-88D7-6ED414281026 Q52657004-D24EF055-362F-4871-804F-7293EABD857B

P2860

Cardiovascular safety profile of currently available diabetic drugs.

http://www.wikidata.org/entity/Q34971736

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cardiovascular safety profile of currently available diabetic drugs.

@ast

Cardiovascular safety profile of currently available diabetic drugs.

@en

Cardiovascular safety profile of currently available diabetic drugs.

@nl

type

label

Cardiovascular safety profile of currently available diabetic drugs.

@ast

Cardiovascular safety profile of currently available diabetic drugs.

@en

Cardiovascular safety profile of currently available diabetic drugs.

@nl

prefLabel

Cardiovascular safety profile of currently available diabetic drugs.

@ast

Cardiovascular safety profile of currently available diabetic drugs.

@en

Cardiovascular safety profile of currently available diabetic drugs.

@nl

P1433

Q34971736-9BA1165E-F3BA-4763-83D0-E1C381D677BC

P1476

Q34971736-3F9C9CFD-571B-4D80-9A54-14C8EB371FC4

P2093

Q34971736-24AE3893-C272-47A8-ABAD-85155FD3AE69

Q34971736-2F4D6EF0-76E9-4772-95BF-6787D2134028

Q34971736-E3778E7D-BFC6-4475-B975-19D04993B0CC

P2860

Q34971736-01D113AC-63D1-4055-85AD-05F6D9248AEC

Q34971736-02F40293-522C-46F5-ADD5-F2294ABA3521

Q34971736-093E62E1-25B8-4B80-9B8C-1EC43B53903B

Q34971736-0BCEBEF7-64C3-4D56-BAF9-8701AEC1315A

Q34971736-11CF11DB-F94E-4460-B6CD-03E03BAFA328

Q34971736-15BE5D98-78C3-4422-B031-32AEB6293B19

Q34971736-1628D149-4A7E-4402-86D2-CB35CD55AD59

Q34971736-16697FEC-DE8E-4367-ACF2-341CC93679A1

Q34971736-187A5E22-FD73-4D81-BD13-720CE8FC69AB

Q34971736-18CD8175-7918-4427-BEF1-F00F2DC1B704

P304

Q34971736-E9D01E37-D95A-4EB6-ABB9-88173A67AEC5

P31

Q34971736-F6DF16E0-BC4A-4DEA-81CF-8DD5BFD22146

P433

Q34971736-326D9A70-BB89-47C5-90E6-2CC924EBE129

P478

Q34971736-74BFAA97-9BFB-4BCA-B235-4DA72FDAA55B

P577

Q34971736-E379CB88-3D17-4DB0-986E-03D3A99F0A69

P698

Q34971736-8977962D-40E6-479C-BAE7-300957D80F62

P921

Q34971736-C397A902-D8F4-4FBB-B8FE-FF3E60628902

P932

Q34971736-10443609-53C8-4C9B-BE2D-0B55B9152F63

P1433

The Ochsner journal

P1476

Cardiovascular safety profile of currently available diabetic drugs.

@en

P2093

Debabrata Mukherjee

http://www.w3.org/2001/XMLSchema#string

Komola Azimova

http://www.w3.org/2001/XMLSchema#string

Zinnia San Juan

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Metformin: safety in cardiac patients

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

P304

616-632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25598727

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

4295739

http://www.w3.org/2001/XMLSchema#string